Last reviewed · How we verify

Comparator: ibuprofen

Organon and Co · Phase 3 active Small molecule

Ibuprofen inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.

Ibuprofen inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever. Used for Mild to moderate pain, Fever reduction, Inflammatory conditions (e.g., rheumatoid arthritis, osteoarthritis).

At a glance

Generic nameComparator: ibuprofen
SponsorOrganon and Co
Drug classNonsteroidal anti-inflammatory drug (NSAID)
TargetCOX-1, COX-2
ModalitySmall molecule
Therapeutic areaPain Management, Inflammation, Rheumatology
PhasePhase 3

Mechanism of action

Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively blocks COX-1 and COX-2 enzymes, which catalyze prostaglandin production. By reducing prostaglandins, it suppresses inflammatory responses and pain signaling. This mechanism also accounts for its antipyretic effects and potential gastrointestinal and cardiovascular side effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: